surmount-1 tirzepatide SURMOUNT-1 Trial

Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity

24.91

★★★★☆4.8 (126)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

29.53

★★★★★4.9 (98)

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight

28.12

★★★★★5.0 (157)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity

22.26

★★★★★4.7 (84)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh

27.74

★★★★★4.9 (203)

SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes

26.94

★★★★★5.0 (176)

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

20.41

★★★★★4.8 (132)